Atrium Therapeutics

Forecast & Rating5 analysts currently cover Atrium Therapeutics, with about 100.0% giving a positive rating — meaning they expect the stock to rise. The average price target is $23.00, about 184.0% upside from the current price of $8.10. Price targets span a fair range, indicating some disagreement among institutions. Historically, about 51.5% of past price targets were eventually met, which adds credibility. For you, this means most professionals who study Atrium Therapeutics closely still see room for the stock to rise. Data as of Oct 23, 2026; for reference only and not investment advice.